No Causal Link Seen Between Stimulant Prescription, Psychotic Experience
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, May 12, 2025 -- Stimulant prescriptions do not appear to have a causal relationship with psychotic experiences, according to a study published online May 12 in Pediatrics.
Kirstie O'Hare, Ph.D., from the Centre for Clinical Brain Sciences at the University of Edinburgh in the United Kingdom, and colleagues estimated the causal effect of stimulants on psychotic experiences in a trial emulated using Adolescent Brain Cognitive Development Study data. The analytical sample included 8,391 participants, aged 9 to 14 years; 460 (5.5 percent) reported one or more prescriptions for a stimulant.
The researchers found that stimulant prescription was associated with subsequent psychotic experiences in unweighted analyses (odds ratio, 1.46). However, the reverse was also true, with baseline psychotic experiences predicting subsequent stimulant treatment (odds ratio, 1.93). No evidence was seen for a causal effect of stimulant prescription on the subsequent occurrence of psychotic experiences when applying doubly robust estimation.
"Our findings suggest that although there is an increased risk of psychotic experiences in children and adolescents who are prescribed stimulant medication, this increased risk is driven by patient characteristics rather than by stimulant treatment itself," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-13 12:00
Read more

- Emergency Department Visits for Asthma Increased During 2023 Wildfires
- FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar to Avastin
- No Greater Risk Of Brain Aging Among People With Autism
- School-Based Asthma Therapy Boosts Asthma Control, Cuts Acute Health Care Use
- DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease
- 2019 to 2023 Saw Increase in Prevalence of Psilocybin Use in the United States
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions